Overview

Study Evaluating IMA-638 in Asthma

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer